|
ARBEITSGRUPPE:
EPIDEMIOLOGIE
UND REISEMEDIZIN
Leiter: a.o. Univ.
Prof. Dr. Herwig Kollaritsch
A d r e s s
e:
Kinderspitalgasse
15, A-1090 Wien
Tel: +43-1-40 160-38200
Fax.: +43-1-40 160-938293
WISSENSCHAFTLICHER
UND BERUFLICHER WERDEGANG
5/1980 Arzt
(Promotion) Universität Wien
1980/1981 Kaiser
Franz Josef-Spital, Abt.f.Infektionskrankheiten
1981 Assistent
am Institut für Spezifische Prophylaxe und
Tropenmedizin, Universität Wien
1982 Diplom
Tropenmedizin am Bernhard Nocht-Institut für
Tropenmedizin, Hamburg
1989 Facharztanerkennung
in Spezifischer Prophylaxe und
Tropenmedizin, Habilitation in Spezifischer Prophylaxe und
Tropenmedizin
1989-1997 Stv.
Institutsvorstand, Institut für Spezifische Prophylaxe und
Tropenmedizin, Universität Wien
1990 Facharztanerkennung
in Hygiene, Mikrobiologie und
Präventivmedizin
1991 Intensivkurs
in Tropenmedizin, Liverpool, UK
1993-1994 Gast-Professor
am Hygiene-Institut, Universität Graz
1989-1997 Stv.
Institutsvorstand, Institut für Spezifische Prophylaxe und
Tropenmedizin, Universität Wien
1993 Tropenmedizin
Update, London School of Hygiene and
Tropical Medicine
1996 Ernennung
zum a.o.Professor, Institut für Spezifische
Prophylaxe und Tropenmedizin, Universität Wien
1997-2004 Leiter
des Instituts für Spezifische Prophylaxe und
Tropenmedizin (ISPTM), Medizinuniversität Wien
2004- Leiter
der Forschungsunit „Epidemiologie und Reisemedizin“am ISPTM
SONSTIGE AKTIVITÄTEN
1985-1987 Feldstudien
zu Malaria in Nigeria, Westafrika
1994-1999 Zahlreiche
Feldstudien zu Reise-Diarrhoe und Impfstoffen (Hepatitis A, B,
Cholera-live)
1996 Gründung
eines landesweiten Überwachungssystems für
durch Impfung zu verhütende Krankheiten in Österreich
1997- Sekretär
The Royal Society of Tropical Medicine and
Hygiene
1997- Gesellschafter
und Leiter im “Zentrum für Reisemedizin”
1999-2001 Präsident
der Österreichischen Gesellschaft für
Tropenmedizin und Parasitologie
Seit 2000 Rezensent
Wiener Klinische Wochenschrift, Journal of
Travel Medicine, Vaccine
2006- Co-Editor
Journal of Travel Medicine
2006- Direktor
am Karl Landsteiner Institut für
Infektionsepidemiologie und Impfwesen
2003- Präsident,
der Österreichischen Gesellschaft für
Reise- und Touristikmedizin
2009- Allgemein
beeideter und gerichtlich zertifizierter
Sachverständiger für Tropenmedizin, Reisemedizin und
Impfwesen
Mitgliedschaften
1983- Österreichische
Gesellschaft für Tropenmedizin und Parasitologie
1984- Royal
Society of Hygiene & Tropical Medicine, UK
1985- Österreichische
Gesellschaft für Infektionskrankheiten
2000- Österreichische
Gesellschaft für Reisemedizin
1999- Mitglied des
“Arzneimittelsicherheits-Ausschusses”
1999-2010 Vizevorsitzender
des Impfausschusses der Obersten Sanitätsrates der Republik
Österreich
2003-2009 Mitglied
der Kommission für Entwicklungsfragen an der Österreichischen
Akademie der Wissenschaften
2007- Mitglied
des “Wehrmedizinischen Beirates am Bundesministerium für
Landesverteidigung
2009- Generalsekretär
des Österr.Grünen Kreuz
2010- Vorstandsmitglied
der Österreichischen Gesellschaft
f.Infektionskrankheiten
Veröffentlichungen
Derzeit ca. 400
akademische Veröffentlichungen, davon dzt.137 in
„peer-reviewten“
medizinischen
Fachjournalen, 13 Bücher, mehr als 20 Buch-Beiträge
Forschungsinteressen und
Aktivitäten:
Vakzinologie, Infektionskrankheiten-Epidemiologie, Reise- und
Tropenmedizin
Wissenschaftliche Mitarbeiter der Arbeitsgruppe:
Mag. Brigitte
Laaber
Dr. Mag. Maria
Paulke-Korinek (bis 31.08.2011 karenziert)
Mag. Birgit
Schmidle-Loss
Dr. Claudia
Seidl-Friedrich
Ines Zwazl
Karenzvertretung:
Dr. Natascha Brodträger
Forschungsprojekte
Ongoing research
projects
Since 1997: Network on epidemiological
surveillance and control of vaccine preventable diseases in hospitalised children,
including acute rotavirus gastroenteritis, Pertussis, hepatitis A, B and C,
mumps, measles and invasive Haemophilus Influenzae Serotype B.
Since 1999: Laboratory-based network on epidemiological
surveillance and control of vaccine preventable diseases, including acute
rotavirus gastroenteritis, Pertussis, hepatitis A, B and C, mumps, measles
and invasive Haemophilus Influenzae Serotype B.
Since 2000: Prospective evaluation of the national incidence of IPD
and serotypes of Streptococcus pneumoniae in children up to 5 years
of age within an observational study
Since 2002: Phase IV TBE vaccination study in
adults – Evaluation of immunogenicity and safety of the polygeline-free
TBE vaccine in adults, when used as booster at least 3 years after primary
or booster TBE immunization.
Since 2005: Long
term immunogenicity of the japanese encephalitis vaccine IC51 (JE-PIV). An
uncontrolled phase 3 follow-up study.
Since 2007: An Open Label Phase III study of a Vero Cell-Derived
whole Virus H5N1 influenza vaccine to assess the Immunogenicity and Safety
and to investigate need for and timing of a Booster Vaccination.
Since
2007: Seroprevalence study regarding relevant vaccine-preventable diseases
in Austrian children aged 5 to 7 years.
Since 2007: Prospective
5-years rotavirus strain surveillance of hospitalized and nonhospitalized
children in Austria.
Planned projects
Efficacy of Rotaviurs vaccination in
Austrian children
K O O P E R A T I
O N E N
Cooperations within the MUW:
Prof. Kundi; Institute of Environmental
Medicine; Statistical analysis of
epidemiological data
Prof. Holzmann, Institute of Virology,
Serology after TBE vaccination, Serotyping of Rotavirus strains, Serology
of measles, mumps, rubella, hepatitis B,
Prof. G. Stanek, Institute for
Hygiene; Surveillance of pertussis epidemiology
Prof. Burgmann; Univ. Clinic of
Internal Medicine: Serotyping and antimicrobial resistance testing of Strep.
Pneum. Isolates
Cooperations
out side MUW:
Prof.
Zenz: Kinderklinik Graz
Prof.
Mutz: Kinderklinik Leoben
Prof. Waldner, Institute for Hygiene, Medical University
Innsbruck
Prof.
Mittermayer, Institute for Hygiene, Krankenhaus Elisabethinen,
Linz
Prof. Harald Stoiber, Medical University
Graz
Federal Ministry of Health and Women
Floridsdorfer Allergiezentum, Wien
Krankenhaus Rudolfstiftung, Wien
Krankenhaus Wilhelminenspital, Wien
St. Anna Kinderkrankenhaus, Wien
Zentrum für Reisemedizin, Wien (Pandemic
Flu Vaccine-Study)
International cooperations:
Clinical studies together with Novartis Vaccines
(TBE), Wyeth Pharma (invasive pneumococcal diseases), Intercell (Japanese
Encephalitis), Baxter (pandemic flu vaccine), SanofiPasteur MSD (Rotavirus
surveillance in hospitalised children), GlaxoSmithKline
P U B L I K
A T I O N E N
1: Kunze U; ISW TBE.
Tick-borne encephalitis: from childhood to golden age does
increased mobility mean
increased risk? Conference report of the 11th meeting of
the International Scientific
Working Group on Tick-Borne Encephalitis (ISW-TBE). Vaccine. 2010 Jan 22;28(4):875-6.
Epub 2009 Nov 27. PubMed PMID: 19945411. IF: 3,616
2: von Krempelhuber A,
Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley
A, Mateo L, Siersbol H,
Kollaritsch H, Chaplin P. A randomized, double-blind,
dose-finding Phase II study
to evaluate immunogenicity and safety of the third
generation smallpox vaccine
candidate IMVAMUNE. Vaccine. 2010 Feb
3;28(5):1209-16. Epub 2009
Nov 25. PubMed PMID: 19944151; PubMed Central PMCID: PMC2814951. IF: 3,616
3: Paulke-Korinek M,
Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal
mass vaccination against
rotavirus gastroenteritis: impact on hospitalization
rates in austrian children.
Pediatr Infect Dis J. 2010 Apr;29(4):319-23. PubMed
PMID: 19935446. IF: 3,312
4: Paulke-Korinek M,
Rendi-Wagner P, Kundi M, Laaber B, Wiedermann U, Kollaritsch
H. Booster vaccinations against tick-borne encephalitis: 6 years
follow-up
indicates long-term
protection. Vaccine. 2009 Nov 23;27(50):7027-30. Epub 2009 Sep 26. PubMed
PMID: 19786143. IF: 3,616
5: Kollaritsch H,
Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese
encephalitis vaccine. Expert
Opin Biol Ther. 2009 Jul;9(7):921-31. Review. PubMed
PMID: 19527110. IF: 3,215
6: Kaltenböck A,
Dubischar-Kastner K, Eder G, Jilg W, Klade
C, Kollaritsch H,
Paulke-Korinek M, von
Sonnenburg F, Spruth M, Tauber E, Wiedermann U, Schuller E.
Safety and immunogenicity of
concomitant vaccination with the cell-culture based
Japanese Encephalitis
vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in
healthy subjects: A
single-blind, randomized, controlled Phase 3 study. Vaccine. 2009 Jul
16;27(33):4483-9. Epub 2009 May 30. PubMed PMID: 19486955. IF: 3,616
7: Rendi-Wagner P,
Paulke-Korinek M, Kundi M, Burgmann H, Georgopoulos A, Vécsei
A, Kollaritsch H. National
paediatric immunization program of high risk groups:
no effect on the incidence
of invasive pneumococcal diseases. Vaccine. 2009 Jun 19;27(30):3963-8. Epub
2009 May 3. PubMed PMID: 19393711. IF: 3,616
8: Paulke-Korinek M,
Rendi-Wagner P, Kundi M, Tomann B, Wiedermann U, Kollaritsch
H. Pretravel consultation: rapid dipstick test as a decision
guidance for the
application of tetanus
booster vaccinations. J Travel Med. 2008
Nov-Dec;15(6):437-41. PubMed
PMID: 19090799. IF: 1,503
9: Kunze U; ISW TBE. Conference
report of the 10th meeting of the international
scientific working group on
tick-borne encephalitis (ISW-TBE): combating
tick-borne encephalitis:
vaccination rates on the rise. Vaccine. 2008 Dec 9;26(52):6738-40. Epub
2008 Nov 11. PubMed PMID: 19007838. IF: 3,616
10: Garner-Spitzer E, Kundi
M, Rendi-Wagner P, Winkler B, Wiedermann G, Holzmann
H, Herzog C, Kollaritsch H,
Wiedermann U. Correlation between humoral and
cellular immune responses
and the expression of the hepatitis A receptor HAVcr-1
on T cells after hepatitis A
re-vaccination in high and low-responder vaccines. Vaccine. 2009 Jan
7;27(2):197-204. Epub 2008 Nov 7. PubMed PMID: 18996424. IF: 3,616
11: Weinke T, Liebold I,
Burchard GD, Frühwein N, Grobusch MP, Hatz C,
Kollaritsch H, Nothdurft HD,
Reisinger E, Rieke B, Schönfeld Ch, Steffen R, Stich
A. Prophylactic immunisation against traveller's diarrhoea caused by
enterotoxin-forming strains of
Escherichia coli and against cholera: does it make
sense and for whom? Travel
Med Infect Dis. 2008 Nov;6(6):362-7. PubMed PMID:
18984481.
12: Schuller E, Klade CS,
Heinz FX, Kollaritsch H, Rendi-Wagner P, Jilma B,
Tauber E. Effect of
pre-existing anti-tick-borne encephalitis virus immunity on
neutralising antibody
response to the Vero cell-derived, inactivated Japanese
encephalitis virus vaccine
candidate IC51. Vaccine. 2008 Nov 11;26(48):6151-6. Epub 2008 Sep 17.
PubMed PMID: 18804132. IF: 3,616
13: Schuller E, Jilma B,
Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C,
Tauber E. Long-term
immunogenicity of the new Vero cell-derived, inactivated
Japanese encephalitis virus vaccine IC51 Six and 12 month results of
a
multicenter follow-up phase
3 study. Vaccine. 2008 Aug 12;26(34):4382-6. Epub 2008 Jun 17. PubMed PMID:
18599165. IF: 3,616
14: Tauber E, Kollaritsch H,
von Sonnenburg F, Lademann M, Jilma B, Firbas C,
Jelinek T, Beckett C,
Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W,
Lyons A. Randomized,
double-blind, placebo-controlled phase 3 trial of the safety
and tolerability of IC51, an
inactivated Japanese encephalitis vaccine. J Infect
Dis. 2008 Aug
15;198(4):493-9. Erratum in: J Infect Dis. 2010 Apr 15;201(8):1278.
PubMed PMID: 18588481. IF:
5,865
15: Jelinek T, Kollaritsch
H. Vaccination with Dukoral against travelers'
diarrhea (ETEC) and cholera.
Expert Rev Vaccines. 2008 Jul;7(5):561-7. Review.
PubMed PMID: 18564011. IF:
4,214
16: Paulke-Korinek M, Kollaritsch
H. [Rabies, a neglected threat]. Med Monatsschr
Pharm. 2008 Feb;31(2):53-8;
quiz 59-60. Review. German. PubMed PMID: 18368978. IF:0
17: Bröker M,
Kollaritsch H. After a tick bite in a tick-borne encephalitis virus
endemic area: current positions
about post-exposure treatment. Vaccine. 2008 Feb
13;26(7):863-8. Epub 2007
Dec 4. Review. PubMed PMID: 18206274. IF: 3,616
18: Raffelsberger J,
Wernsdorfer G, Sirichaisinthop J, Kollaritsch H, Congpuong
K, Wernsdorfer WH.
Pharmacodynamic interaction between monodesbutyl-benflumetol
and artemisinin as well as
proguanil in Plasmodium falciparum in vitro. Wien Klin
Wochenschr. 2008;120(19-20
Suppl 4):90-4. PubMed PMID: 19066781. IF: 0,955
19: Starzengruber P,
Kollaritsch H, Sirichaisinthop J, Wernsdorfer G, Congpuong
K, Wernsdorfer WH.
Interaction between lumefantrine and monodesbutyl-benflumetol
in Plasmodium falciparum in
vitro. Wien Klin Wochenschr. 2008;120(19-20 Suppl
4):85-9. PubMed PMID:
19066780. IF: 0,955
20: Paulke-Korinek M,
Kollaritsch H. Japanese encephalitis and vaccines: past and
future prospects. Wien Klin
Wochenschr. 2008;120(19-20 Suppl 4):15-9. Review.
PubMed PMID: 19066766. IF:
0,955
21: Tauber E, Kollaritsch H,
Korinek M, Rendi-Wagner P, Jilma B, Firbas C,
Schranz S, Jong E, Klingler
A, Dewasthaly S, Klade CS. Safety and immunogenicity
of a Vero-cell-derived,
inactivated Japanese encephalitis vaccine: a
non-inferiority, phase III,
randomised controlled trial. Lancet. 2007 Dec
1;370(9602):1847-53. PubMed
PMID: 18061060. IF: 30.758
22: Kollaritsch H, Wenisch
C, Hatz C, von Laer G, Bauer B, Hollenstein U,
Haditsch M, Diridl G,
Malinowski W, Jeschko E, Payer-Neundlinger G, Speiser-Remp
N, Pichler HE, Rumpold H,
Stemberger H, Eder G, Wiedermann G, Wiedermann U.
[Medical clearance for
missions abroad (EEU): definitions, recommendations for
use and performance]. Wien
Klin Wochenschr. 2007;119(19-20 Suppl 3):13-25. Review. German. Erratum in:
Wien Klin Wochenschr. 2009 Oct;121 Suppl 3:following
56. PubMed PMID: 17987354.
IF: 0,955
23: Rendi-Wagner P,
Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact
of a pertussis booster
vaccination program in adolescents and adults on the
epidemiology of pertussis in
Austria.
Pediatr Infect Dis J. 2007
Sep;26(9):806-10. PubMed
PMID: 17721375. IF: 3,312
24: Rendi-Wagner P, Korinek
M, Mikolasek A, Vécsei A, Kollaritsch H. Epidemiology
of travel-associated and
autochthonous hepatitis A in Austrian children, 1998 to
2005. J Travel Med. 2007
Jul-Aug;14(4):248-53. PubMed PMID: 17617847. IF: 1,503
25: Rendi-Wagner P,
Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B,
Kollaritsch H. Antibody persistence following booster vaccination
against
tick-borne encephalitis: 3-year
post-booster follow-up. Vaccine. 2007 Jun 28;25(27):5097-101. Epub 2007 Feb
20. PubMed PMID: 17555850. IF: 3,616
26: Nothdurft HD, Dahlgren AL, Gallagher EA,
Kollaritsch H, Overbosch D,
Rummukainen ML, Rendi-Wagner
P, Steffen R, Van Damme P; ad hoc Travel Medicine
Expert Panel for ESENEM. The
risk of acquiring hepatitis A and B among travelers
in selected Eastern and Southern Europe and non-European Mediterranean
countries:
review and consensus
statement on hepatitis A and B vaccination. J Travel Med.
2007 May-Jun;14(3):181-7.
PubMed PMID: 17437475. IF: 1,503
27: Kollaritsch H, Wiedermann U. [Examples for vaccines against
diarrheal
diseases--rotavirus and
traveller's diarrhea]. Wien Med Wochenschr.
2007;157(5-6):102-6. Review.
German. PubMed PMID: 17427005. IF:0
28: Starzengruber P,
Wernsdorfer G, Parizek M, Rojanawatsirivet C, Kollaritsch H,
Wernsdorfer WH. Specific
pharmacokinetic interaction between lumefantrine and
monodesbutyl-benflumetol in
Plasmodium falciparum. Wien Klin Wochenschr.
2007;119(19-20 Suppl
3):60-6. Erratum in: Wien Klin Wochenschr. 2009 Oct;121
Suppl 3:following 56. PubMed
PMID: 17987360. IF: 0,955
29: Parizek M,
Sirichaisinthop J, Wernsdorfer G, Noedl H, Kollaritsch H,
Wernsdorfer WH. Synergistic
interaction between monodesbutyl-benflumetol and
retinol in Plasmodium
falciparum. Wien Klin Wochenschr. 2007;119(19-20 Suppl
3):53-9. Erratum in: Wien
Klin Wochenschr. 2009 Oct;121 Suppl 3:following 56.
PubMed PMID: 17987359. IF:
0,955
30: Exner B, Wernsdorfer G, Sirichaisinthop
J, Rojanawatsirivet C, Kollaritsch H,
Wernsdorfer WH. Synergistic
interaction between atovaquone and retinol in
Plasmodium falciparum in
vitro. Wien Klin Wochenschr. 2007;119(19-20 Suppl
3):45-52. Erratum in: Wien
Klin Wochenschr. 2009 Oct;121 Suppl 3:following 56.
PubMed PMID: 17987358. IF:
0,955
31: Lütgendorf C,
Rojanawatsirivet C, Wernsdorfer G, Sirichaisinthop J,
Kollaritsch H, Wernsdorfer
WH. Pharmacodynamic interaction between atovaquone and
other antimalarial compounds
against Plasmodium falciparum in vitro. Wien Klin
Wochenschr. 2006;118(19-20
Suppl 3):70-6. PubMed PMID: 17131244. IF: 0,955
32: Kyavar L,
Rojanawatsirivet C, Kollaritsch H, Wernsdorfer G, Sirichaisinthop
J, Wernsdorfer WH. In vitro
interaction between artemisinin and chloroquine as
well as desbutyl-benflumetol
in Plasmodium vivax. Wien Klin Wochenschr.
2006;118(19-20 Suppl
3):62-9. PubMed PMID: 17131243. IF: 0,955
33: Wiedermann U,
Kollaritsch H. Vaccines against traveler's diarrhoea and
rotavirus disease - a review.
Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):2-8.
Review. PubMed PMID:
17131234. IF: 0,955
34: Rendi-Wagner P, Korinek
M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U.
Persistence of seroprotection
10 years after primary hepatitis A vaccination in
an unselected study
population. Vaccine. 2007 Jan 15;25(5):927-31. Epub 2006 Sep 18. PubMed
PMID: 17005304. IF: 3,616
35: Kollaritsch H, Maurer W.
[Rabies: epidemiology, pre- and postexposure
immunization]. Wien Klin
Wochenschr. 2006 Jun;118(11-12):312-20. Review. German.
PubMed PMID: 16855918. IF:
0,955
36: Weinke T, Liebold I,
Burchard GD, Frühwein N, Grobusch MP, Hatz C,
Kollaritsch H, Nothdurft HD,
Reisinger E, Rieke B, Schönfeld Ch, Steffen R, Stich
A. [Prophylactic
immunization against enterotoxin-forming Escherichia coli
travellers' diarrhea and
cholera: does it make sense and for whom?]. Dtsch Med
Wochenschr. 2006 Jul
28;131(30):1660-4. Review. German. PubMed PMID: 16850383.
IF: 0,590
37: Rendi-Wagner P, Kundi M,
Mikolasek A, Mutz I, Zwiauer K, Wiedermann U, Vécsei
A, Kollaritsch H. Active
hospital-based surveillance of rotavirus diarrhea in
Austrian children, period 1997 to 2003. Wien Klin Wochenschr. 2006
May;118(9-10):280-5. PubMed
PMID: 16810486. IF: 0,955
38: Rendi-Wagner P, Kundi M,
Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H.
Hospital-based active
surveillance of childhood pertussis in Austria from 1996 to
2003: estimates of incidence and vaccine effectiveness of whole-cell
and
acellular vaccine. Vaccine.
2006 Aug 14;24(33-34):5960-5. Epub 2006 May 23.
PubMed PMID: 16757063. IF:
3,616
39: Rendi-Wagner P, Zent O,
Jilg W, Plentz A, Beran J, Kollaritsch H. Persistence
of antibodies after
vaccination against tick-borne encephalitis. Int J Med
Microbiol. 2006 May;296
Suppl 40:202-7. Epub 2006 Mar 9. Review. PubMed PMID:
16524776. IF: 3,047
40: Rendi-Wagner P, Shouval
D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A,
Heim M, Bach D, Schroeder M,
Kollaritsch H. Comparative immunogenicity of a
PreS/S hepatitis B vaccine
in non- and low responders to conventional vaccine.
Vaccine. 2006 Apr
5;24(15):2781-9. Epub 2006 Jan 19. PubMed PMID: 16455169. IF: 3,616
41: Thriemer K, Wernsdorfer
G, Rojanawatsirivet C, Kollaritsch H,
Sirichainsinthop J,
Wernsdorfer WH. In vitro activity of artemisinin alone and in
combination with retinol
against Plasmodium falciparum. Wien Klin Wochenschr.
2005;117 Suppl 4:45-8.
PubMed PMID: 16416385. IF: 0,955
42: Samal D,
Rojanawatsirivet C, Wernsdorfer G, Kollaritsch H, Sirichaisinthop J,
Wernsdorfer WH. Synergism of
desbutyl-benflumetol and retinol against Plasmodium
falciparum in vitro. Wien
Klin Wochenschr. 2005;117 Suppl 4:39-44. PubMed PMID:
16416384. IF: 0,955
43: Attlmayr B, Kollaritsch
H, Wernsdorfer WH, Miller RS, Sirichaisinthop J,
Noedl H. Drug sensitivity of
Plasmodium falciparum along the Thai-Myanmar border
using the new field-deployable
HRP2 in vitro assay. Wien Klin Wochenschr.
2005;117 Suppl 4:35-8.
PubMed PMID: 16416383. IF: 0,955
44: Rendi-Wagner P, Jeschko
E, Kollaritsch H; österreichische Expertengruppe für
Reisemedizin. [Travel
vaccination recommendations for Central and Eastern
European countries based on country-specific risk profiles]. Wien
Klin
Wochenschr. 2005;117 Suppl
4:11-9. Review. German. PubMed PMID: 16416380. IF: 0,955
45: Noedl H, Bronnert J,
Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. Simple
histidine-rich protein 2
double-site sandwich enzyme-linked immunosorbent assay
for use in malaria drug
sensitivity testing. Antimicrob Agents Chemother. 2005
Aug;49(8):3575-7. PubMed
PMID: 16048989; PubMed Central PMCID: PMC1196223.
IF: 4,819
46: Rendi-Wagner P, Hoeller
K, Kollaritsch H; Osterreichische Expertengruppe für
Reisemedizin. [Immunization
recommendations for travel in the Mediterranean
area]. Wien Klin Wochenschr.
2004 Oct 30;116(19-20):652-60. German. PubMed PMID:
15941073. IF: 0,955
47: Nothdurft HD, Bialek R,
Burchard GD, Hatz C, Jelinek T, Kollaritsch H,
Schönfeld C, Volkmer
KJ; Ausschuss "Reisemedizin" der Deutschen Gesellschaft für
Tropenmedizin und
Internationale Gesundheit. [Consensus recommendations for
malaria prophylaxis]. Dtsch
Med Wochenschr. 2005 Jun 3;130(22):1392-6. Review.
German. PubMed PMID:
15915383. IF: 0,590
48: Pirker-Krassnig DK,
Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C,
Kollaritsch H, Wernsdorfer
WH. Comparative study on the in vitro activity of
lumefantrine and
desbutyl-benflumetol in fresh isolates of Plasmodium vivax from
Thailand. Wien Klin Wochenschr. 2004;116 Suppl 4:47-52.
PubMed PMID: 15683043.
IF: 0,955
49: Woitsch B, Wernsdorfer
G, Prajakwong S, Rojanawatsirivet C, Kollaritsch H,
Wernsdorfer WH. Comparative
study of the in vitro sensitivity of Plasmodium
falciparum to artemisinin in
two border areas of Thailand.
Wien Klin Wochenschr.
2004;116 Suppl 4:35-40.
PubMed PMID: 15683041. IF: 0,955
50: Noedl H, Attlmayr B,
Wernsdorfer WH, Kollaritsch H, Miller RS. A
histidine-rich protein
2-based malaria drug sensitivity assay for field use. Am J
Trop Med Hyg. 2004
Dec;71(6):711-4. PubMed PMID: 15642959. IF: 2,907
51: Rendi-Wagner P, Kundi M,
Zent O, Banzhoff A, Jaehnig P, Stemberger R, Dvorak
G, Grumbeck E, Laaber B,
Kollaritsch H. Immunogenicity and safety of a booster
vaccination against
tick-borne encephalitis more than 3 years following the last
immunisation. Vaccine. 2004
Dec 9;23(4):427-34. PubMed PMID: 15530690. IF: 3,616
52: Lux D, Prajakwong S,
Kollaritsch H, Wernsdorfer G, Wernsdorfer WH. In-vitro
sensitivity testing of
Plasmodium vivax: response to lumefantrine and chloroquine
in northwestern Thailand.
Wien Klin Wochenschr. 2003;115 Suppl 3:50-4. PubMed
PMID: 15508781. IF: 0,955
53: Ogwang S, Engl M, Vigl
M, Kollaritsch H, Wiedermann G, Wernsdorfer WH.
Clinical and parasitological
response of Plasmodium falciparum to chloroquine and
sulfadoxine/pyrimethamine in
rural Uganda.
Wien Klin Wochenschr. 2003;115 Suppl
3:45-9. PubMed PMID:
15508780. IF: 0,955
54: Noedl H, Wernsdorfer WH,
Kollaritsch H, Looareesuwan S, Miller RS,
Wongsrichanalai C. Malaria
drug-susceptibility testing. HRP2-based assays:
current data, future
perspectives. Wien Klin Wochenschr. 2003;115 Suppl 3:23-7.
PubMed PMID: 15508776. IF:
0,955
55: Wichmann O, Muehlberger
N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen
M, Grobusch MP, Gascon J,
Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros
J, Hatz C, Gjorup I,
McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H,
Kern P, Fry G, Richter J;
European Network on Surveillance of Imported Infectious
Diseases. Screening for
mutations related to atovaquone/proguanil resistance in
treatment failures and other
imported isolates of Plasmodium falciparum in
Europe. J Infect Dis. 2004 Nov 1;190(9):1541-6. Epub
2004 Sep 28. PubMed PMID:
15478057. IF: 5,865
56: Loebermann M,
Kollaritsch H, Ziegler T, Rendi-Wagner P, Chambonneau L, Dumas
R, Lafrenz M. A randomized, open-label study of the immunogenicity
and
reactogenicity of three lots
of a combined typhoid fever/hepatitis A vaccine in
healthy adults. Clin Ther.
2004 Jul;26(7):1084-91. PubMed PMID: 15336473. IF: 3,379
57: Rendi-Wagner P, Kundi M,
Zent O, Dvorak G, Jaehnig P, Holzmann H, Mikolasek
A, Kollaritsch H.
Persistence of protective immunity following vaccination
against tick-borne
encephalitis--longer than expected? Vaccine. 2004 Jul
29;22(21-22):2743-9. PubMed
PMID: 15246606. IF: 3,616
58: Ambrosch F, Finkel B,
Herzog C, Koren A, Kollaritsch H. Rapid antibody
response after vaccination
with a virosomal hepatitis a vaccine. Infection. 2004
Jun;32(3):149-52. Erratum
in: Infection. 2004 Aug;32(4):249. PubMed PMID:
15188074. IF: 2,051
59: Rendi-Wagner P,
Georgopoulos A, Kundi M, Mutz I, Mattauch M, Nowak J,
Mikolasek A, Vecsei A,
Kollaritsch H. Prospective surveillance of incidence,
serotypes and antimicrobial
susceptibility of invasive Streptococcus pneumoniae
among hospitalized children
in Austria.
J Antimicrob Chemother. 2004
May;53(5):826-31. Epub 2004
Apr 8. PubMed PMID: 15073163. IF: 4,352
60: Mühlberger N,
Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J,
Gjørup I, Behrens RH,
Clerinx J, Björkman A, McWhinney P, Matteelli A,
Lopez-Velez R, Bisoffi Z,
Hellgren U, Puente S, Schmid ML, Myrvang B,
Holthoff-Stich ML, Laferl H,
Hatz C, Kollaritsch H, Kapaun A, Knobloch J, Iversen
J, Kotlowski A, Malvy DJ,
Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul
M, Gómez i Prat J,
Lehmann V, Bouchaud O, da Cunha S, Atouguia J, Boecken G.
Epidemiology and clinical
features of vivax malaria imported to Europe:
sentinel
surveillance data from
TropNetEurop. Malar J. 2004 Mar 8;3:5. PubMed PMID:
15003128; PubMed Central PMCID:
PMC385246. IF: 3,150
61: Reinthaler FF, Feierl G,
Beubler E, Kollaritsch H, Ruckenbauer G, Klem G,
Wendelin I, Marth E.
Treatment of travelers' diarrhea among Austrian tourists. J
Travel Med. 2004
Jan-Feb;11(1):66-8. PubMed PMID: 14769292. IF: 1,503
62: Eder
G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion
of a tick-borne encephalitis
vaccine in children. Vaccine. 2003 Sep
8;21(25-26):3575-83. PubMed
PMID: 12922085. IF: 3,616
63: Wichmann O, Jelinek T,
Peyerl-Hoffmann G, Mühlberger N, Grobusch MP, Gascon
J, Matteelli A, Hatz C,
Laferl H, Schulze M, Burchard G, da Cunha S, Beran J,
McWhinney P, Kollaritsch H,
Kern P, Cuadros J, Alifrangis M, Gjørup I; European
Network on Surveillance of
Imported Infectious Diseases (TropNetEurop). Molecular
surveillance of the
antifolate-resistant mutation I164L in imported African
isolates of Plasmodium
falciparum in Europe: sentinel data from
TropNetEurop.
Malar J. 2003 Jun 25;2:17.
Epub 2003 Jun 25. PubMed PMID: 12869209; PubMed
Central
PMCID: PMC166141. IF:
3,150
64: Noedl H, Wongsrichanalai
C, Miller RS, Myint KS, Looareesuwan S, Sukthana Y,
Wongchotigul V, Kollaritsch
H, Wiedermann G, Wernsdorfer WH. Plasmodium
falciparum: effect of
anti-malarial drugs on the production and secretion
characteristics of
histidine-rich protein II. Exp Parasitol. 2002
Nov-Dec;102(3-4):157-63.
PubMed PMID: 12856311. IF: 1,776
65: Melzer H, Baier K,
Felici F, von Specht BU, Wiedermann G, Kollaritsch H,
Wiedermann U, Duchêne
M. Humoral immune response against proteophosphoglycan
surface antigens of
Entamoeba histolytica elicited by immunization with synthetic
mimotope peptides. FEMS
Immunol Med Microbiol. 2003 Jul 15;37(2-3):179-83. PubMed
PMID: 12832123. IF: 2,352
66: Steffen R, Kollaritsch
H, Fleischer K. Travelers' diarrhea in the new
millennium: consensus among
experts from German-speaking countries. J Travel Med.
2003 Jan-Feb;10(1):38-45. Review. Erratum in: J Travel Med. 2003
May-Jun;10(3):199. PubMed
PMID: 12729511. IF: 1,503
67: Mühlberger N, Jelinek
T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, Puente
S, Burchard G, Gascon J,
Grobusch MP, Weitzel T, Zoller T, Kollaritsch H, Beran
J, Iversen J, Hatz C, Schmid
ML, Björkman A, Fleischer K, Bisoffi Z, Guggemos W,
Knobloch J, Matteelli A,
Schulze MH, Laferl H, Kapaun A, McWhinney P, Lopez-Velez
R, Fätkenheuer G, Kern
P, Zieger BW, Kotlowski A, Fry G, Cuadros J, Myrvang B;
TropNetEurop; Surveillance
importierter Infektionen in Deutschland Surveillance
Networks. Age as a risk
factor for severe manifestations and fatal outcome of
falciparum malaria in
European patients: observations from TropNetEurop and
SIMPID Surveillance Data.
Clin Infect Dis. 2003 Apr 15;36(8):990-5. Epub 2003 Apr
2. PubMed PMID: 12684911.
IF: 8,195
68: Jelinek T, Peyerl-Hoffmann
G, Mühlberger N, Wichmann O, Wilhelm M, Schmider
N, Grobusch MP, von
Sonnenburg F, Gascon J, Laferl H, Hatz C, Alifrangis M,
Burchard G, McWhinney P,
Schulze M, Kollaritsch H, da Cunha S, Beran J, Kern P,
Gjørup I, Cuadros J.
Molecular surveillance of drug resistance through imported
isolates of Plasmodium
falciparum in Europe. Malar J. 2002 Oct
11;1:11. Epub 2002
Oct 11. PubMed PMID:
12423552; PubMed Central PMCID: PMC140139. IF: 3,150
69: Rendi-Wagner P,
Wiedermann G, Stemberger H, Kollaritsch H. New vaccination
strategies for low- and
non-responders to hepatitis B vaccine. Wien Klin
Wochenschr. 2002 Mar
28;114(5-6):175-80. Review. PubMed PMID: 12238305. IF: 0,955
70: Wiedermann G,
Kollaritsch H, Kundi M, Wernsdorfer WH. Relationships between
mefloquine blood levels,
gender, and adverse reactions. Am J Trop Med Hyg. 2002
May;66(5):445-6; author
reply 446-7. PubMed PMID: 12201572. IF: 2,907
71: Melzer H, Fortugno P,
Mansouri E, Felici F, Marinets A, Wiedermann G,
Kollaritsch H, Von Specht
BU, Duchêne M. Antigenicity and immunogenicity of phage
library-selected peptide
mimics of the major surface proteophosphoglycan antigens
of Entamoeba histolytica.
Parasite Immunol. 2002 Jun;24(6):321-8. PubMed PMID:
12102717. IF: 2,210
72: Noedl H, Wernsdorfer WH,
Krudsood S, Wilairatana P, Wiedermann G, Kollaritsch
H, Looareesuwan S.
Predictive role of laboratory and clinical treatment response
parameters and
glucose-6-phosphate dehydrogenase status in the therapy of
falciparum malaria. Wien
Klin Wochenschr. 2002 Feb 28;114(4):158-63. PubMed PMID:
12060982. IF: 0,955
73: Rendi-Wagner P,
Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin
Infect Dis. 2002 Mar
1;34(5):628-33. Epub 2002 Jan 16. PubMed PMID: 11803509.
IF: 8,195
74: Jelinek T, Schulte C,
Behrens R, Grobusch MP, Coulaud JP, Bisoffi Z,
Matteelli A, Clerinx J,
Corachán M, Puente S, Gjørup I, Harms G, Kollaritsch H,
Kotlowski A, Björkmann
A, Delmont JP, Knobloch J, Nielsen LN, Cuadros J, Hatz C,
Beran J, Schmid ML, Schulze
M, Lopez-Velez R, Fleischer K, Kapaun A, McWhinney P,
Kern P, Atougia J, Fry G, da
Cunha S, Boecken G. Imported Falciparum malaria in
Europe: sentinel surveillance data from the European
network on surveillance of
imported infectious
diseases. Clin Infect Dis. 2002 Mar 1;34(5):572-6. Epub 2002
Jan 21. PubMed PMID:
11803507. IF: 8,195
75: Rendi-Wagner P, Noedl H,
Wernsdorfer WH, Wiedermann G, Mikolasek A,
Kollaritsch H. Unexpected
frequency, duration and spectrum of adverse events
after therapeutic dose of
mefloquine in healthy adults. Acta Trop. 2002
Feb;81(2):167-73. PubMed
PMID: 11801224. IF: 2,446
76: Noedl H, Wernsdorfer WH,
Krudsood S, Wilairatana P, Viriyavejakul P,
Kollaritsch H, Wiedermann G,
Looareesuwan S. In vivo-in vitro model for the
assessment of clinically
relevant antimalarial cross-resistance. Am J Trop Med
Hyg. 2001 Dec;65(6):696-9.
PubMed PMID: 11791959. IF: 2,907
77: Sponer U, Prajakwong S,
Wiedermann G, Kollaritsch H, Wernsdorfer G,
Wernsdorfer WH.
Pharmacodynamic interaction of doxycycline and artemisinin in
Plasmodium falciparum.
Antimicrob Agents Chemother. 2002 Jan;46(1):262-4. PubMed
PMID: 11751150; PubMed
Central PMCID: PMC126969. IF: 4,819
78: Noedl H, Wernsdorfer WH,
Krudsood S, Wilairatana P, Kollaritsch H, Wiedermann
G, Looareesuwan S.
Antimalarial activity of azithromycin, artemisinin and
dihydroartemisinin in fresh
isolates of Plasmodium falciparum in Thailand. Acta
Trop. 2001 Sep
1;80(1):39-44. PubMed PMID: 11495642. IF: 2,446
79: Seifert K, Duchêne
M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann
G, Hottkowitz T, Eibl H.
Effects of miltefosine and other alkylphosphocholines on
human intestinal parasite
Entamoeba histolytica. Antimicrob Agents Chemother.
2001 May;45(5):1505-10.
PubMed PMID: 11302818; PubMed Central PMCID: PMC90496. IF: 4,819
80: Rendi-Wagner P, Kundi M,
Stemberger H, Wiedermann G, Holzmann H, Hofer M,
Wiesinger K, Kollaritsch H.
Antibody-response to three recombinant hepatitis B
vaccines: comparative
evaluation of multicenter travel-clinic based experience.
Vaccine. 2001 Feb
28;19(15-16):2055-60. PubMed PMID: 11228377. IF: 3,616
81: Wiedermann U, Kundi M,
Vollmann U, Kollaritsch H, Ebner C, Wiedermann G.
Different HBs antibody versus
lymphoproliferative responses after application of
a monovalent (hepatitis B)
or combined (hepatitis A + hepatitis B) vaccine. Int
Arch Allergy Immunol. 2000
Dec;123(4):349-53. PubMed PMID: 11146393. IF: 2,542
82: Marlovits S, Stocker R,
Efstratiou A, Broughton K, Kaider A, Vécsei V,
Wiedermann G, Kollaritsch H.
Seroprevalence of diphtheria immunity among injured
adults in Austria.
Vaccine. 2000 Dec 8;19(9-10):1061-7. PubMed PMID: 11137240.
IF: 3,616
83: Melzer H, Felici F,
Mansouri E, Fortugno P, Marinets A, Wiedermann G,
Kollaritsch H, von Specht B,
Duchêne M. Isolation of phage mimotopes mimicking a
protective epitope of
GPI-linked proteophosphoglycan antigens of Entamoeba
histolytica. Arch Med Res.
2000 Jul-Aug;31(4 Suppl):S309-10. PubMed PMID:
11070328. IF: 1,995
84: Seifert K, Duchêne
M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann
G, Eibl H. A new approach
for chemotherapy against Entamoeba histolytica. Arch
Med Res. 2000 Jul-Aug;31(4
Suppl):S6-7. PubMed PMID: 11070202. IF: 1,995
85: Jelinek T, Grobusch M,
Harms-Zwingenberger G, Kollaritsch H, Richter J,
Zieger B. Falciparum malaria
in European tourists to the Dominican
Republic.
Emerg Infect Dis. 2000
Sep-Oct;6(5):537-8. PubMed PMID: 10998386; PubMed Central
PMCID: PMC2627955. IF: 6,794
86: Marlovits S, Stocker R,
Efstratiou A, Broughton K, Kaider A, Vécsei V,
Kollaritsch H. Effect on
diphtheria immunity of combined tetanus and diphtheria
booster vaccination in
adults. Eur J Clin Microbiol Infect Dis. 2000
Jul;19(7):506-13. PubMed
PMID: 10968321. IF: 2,605
87: Frey S, Dagan R, Ashur
Y, Chen XQ, Ibarra J, Kollaritsch H, Mazur MH, Poland
GA, Reisinger K, Walter E,
Van Damme P, Braconier JH, Uhnoo I I, Wahl M, Blatter
MM, Clements D, Greenberg D,
Jacobson RM, Norrby SR, Rowe M, Shouval D, Simmons
SS, van Hattum J, Wennerholm
S, O'Brien Gress J, Chan I I. Reply. J Infect Dis.
2000 Sep;182(3):1005-6.
PubMed PMID: 10950808. IF: 5,865
88: Zenz W, Trop M,
Kollaritsch H, Reinthaler F. [Congenital malaria due to
Plasmodium falciparum and
Plasmodium malariae]. Wien Klin Wochenschr. 2000 May
19;112(10):459-61. German.
PubMed PMID: 10890139. IF: 0,955
89: Kollaritsch H, Karbwang
J, Wiedermann G, Mikolasek A, Na-Bangchang K,
Wernsdorfer WH. Mefloquine
concentration profiles during prophylactic dose
regimens. Wien Klin
Wochenschr. 2000 May 19;112(10):441-7. PubMed PMID: 10890135. IF: 0,955
90: Kollaritsch H, Cryz SJ
Jr, Lang AB, Herzog C, Que JU, Wiedermann G. Local and
systemic immune responses to
combined vibrio cholerae CVD103-HgR and salmonella
typhi ty21a live oral
vaccines after primary immunization and reimmunization.
Vaccine. 2000 Jul
1;18(26):3031-9. PubMed PMID: 10825607. IF: 3,616
91: Wiedermann G, Kollaritsch
H, Kundi M, Svennerholm AM, Bjare U. Double-blind,
randomized, placebo
controlled pilot study evaluating efficacy and reactogenicity
of an oral ETEC
B-subunit-inactivated whole cell vaccine against travelers'
diarrhea (preliminary
report). J Travel Med. 2000 Jan;7(1):27-9. PubMed PMID:
10689236. IF: 1,503
92: Frey S, Dagan R, Ashur
Y, Chen XQ, Ibarra J, Kollaritsch H, Mazur MH, Poland
GA, Reisinger K, Walter E,
Van Damme P, Braconier JH, Uhnoo I, Wahl M, Blatter
MM, Clements D, Greenberg D,
Jacobson RM, Norrby SR, Rowe M, Shouval D, Simmons
SS, van Hattum J, Wennerholm
S, Gress JO, et al. Interference of antibody
production to hepatitis B
surface antigen in a combination hepatitis A/hepatitis
B vaccine. J Infect Dis.
1999 Dec;180(6):2018-22. Erratum in: J Infect Dis 2000
Feb;181(2):814. PubMed PMID:
10558961. IF: 5,865
93: Kollaritsch H.
[Travellers' diarrhea]. Internist (Berl). 1999
Nov;40(11):1132-6. Review.
German. PubMed PMID: 10556326.IF:0
94: Kollaritsch H. [Travel
medicine. Unde venis?]. Wien Klin Wochenschr. 1999 Aug
20;111(15):578-81. Review.
German. PubMed PMID: 10483671. IF: 0,955
95: Tsai TF, Kollaritsch H,
Que JU, Cropp CB, Kunz C, Wiedermann G, Herzog C,
Cryz SJ. Compatible
concurrent administration of yellow fever 17D vaccine with
oral, live, attenuated
p6olera CVD103-HgR and typhoid ty21a vaccines. J Infect
Dis. 1999 Feb;179(2):522-4.
PubMed PMID: 9878043. IF: 5,865
|
